Prevention of new osteitis on magnetic resonance imaging in patients with early axial spondyloarthritis during 3 years of continuous treatment with etanercept: data of the ESTHER trial.
暂无分享,去创建一个
J. Listing | J. Sieper | B. Freundlich | K. Hermann | H. Haibel | D. Poddubnyy | M. Rudwaleit | A. Weiß | C. Althoff | I. Song | E. Lange
[1] A. Deodhar,et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study , 2012, Annals of the rheumatic diseases.
[2] V. Mazurov,et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1 , 2013, Annals of the rheumatic diseases.
[3] J. Braun,et al. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis , 2013, Annals of the rheumatic diseases.
[4] J. Reveille,et al. The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. , 2013, Arthritis and rheumatism.
[5] D. M. van der Heijde,et al. THU0431 Localisation of bone marrow edema in sacroiliac joints in spondyloarthritis patients: Does the site of lesions change over a 3-month period? , 2013 .
[6] W. Maksymowych,et al. Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification , 2012, Annals of the rheumatic diseases.
[7] G. Burmester,et al. Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial , 2012, Annals of the rheumatic diseases.
[8] A. Deodhar,et al. Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study , 2011, Annals of the rheumatic diseases.
[9] A. Deodhar,et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study , 2011, Annals of the rheumatic diseases.
[10] Andreas Krause,et al. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial , 2011, Annals of the rheumatic diseases.
[11] M. Dougados,et al. Arthritis 2 Spondyloarthritis , 2011 .
[12] L. Coates,et al. Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. , 2009, Arthritis and rheumatism.
[13] J. Braun,et al. Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. , 2008, Arthritis and rheumatism.
[14] P. Rahman,et al. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study. , 2007, Arthritis and rheumatism.
[15] R. Landewé,et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. , 2006, Arthritis and rheumatism.
[16] Jürgen Braun,et al. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. , 2006, Arthritis and rheumatism.
[17] J. Braun,et al. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. , 2005, Rheumatology.
[18] John C. Davis,et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor α receptor fusion protein etanercept , 2005 .